SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

Starknet is generating buzz with notable growth across its ecosystem, evidenced by increasing Total Value Locked and app revenue reaching new highs. Its expansion to Solana and the integration of native USDC are key talking points, showcasing its evolving infrastructure. The community is actively discussing Starknet's advanced ZK-STARKs technology for quantum resistance and scalability, alongside its native Account Abstraction, positioning it as a significant layer for both Bitcoin and Ethereum activity.

SSgA Active Trust - State Street Consumer Staples Select Sector SPDR ETF

Consumer Staples Select Sector SPDR Fund

The Consumer Staples Select Sector SPDR Fund (XLP) is attracting significant attention, with community discussions centered on its strong bullish momentum and transition from a defensive to an offensive market stance. Traders are actively noting technical breakouts and the reclaiming of key resistance levels, interpreting these as signals for a potential sustained uptrend as capital shifts towards essential goods. This heightened interest, following a period of underperformance, is also being viewed through historical patterns that suggest further outperformance.

Medical Properties Trust, Inc. is a self-advised real estate investment trust. It engages in the investment, acquisition, and development of net-leased healthcare facilities. Its property portfolio includes rehabilitation hospitals, long-term acute care hospitals, ambulatory surgery centers, hospitals for women and children, regional and community hospitals, medical office buildings, and other single-discipline facilities. The company was founded by Edward K. Aldag Jr., R. Steven Hamner, Emmett E. McLean, and William Gilliard McKenzie in 2003 and is headquartered in Birmingham, AL.

Medical Properties Trust Inc

Medical Properties Trust is actively trending as a recent dividend hike and a substantial share repurchase authorization ignite strong debate among investors. Many bulls anticipate a significant short squeeze and long-term appreciation, pointing to perceived undervaluation and improving fundamentals, while skeptics emphasize ongoing risks from tenant solvency and the broader healthcare landscape. Community discussion is focused on whether these positive catalysts are enough to overcome persistent bearish sentiment and drive a sustained rebound.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

Fannie Mae is actively discussed following directives for increased mortgage bond purchases, sparking a polarized debate on whether this move strengthens the path to recapitalization and an IPO or signals further delays. The community is grappling with the implications for its long-awaited release from conservatorship and potential NYSE listing, amid ongoing frustration over market volatility.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is a top trending stock as the community eagerly anticipates crucial data readouts for its oral ITK inhibitor, soquelitinib. Upcoming results for both T-cell lymphoma and a placebo-controlled Atopic Dermatitis Cohort 4 trial are expected in January, with investors focused on efficacy, durability, and biomarker data that could establish a novel, best-in-class oral option in a significant market. Speculation around potential partnerships or acquisitions, fueled by recent board appointments and conference changes, is also driving intense conversation about the stock's valuation and future.

Reactive Network is the first parallelized interoperability execution layer, utilising a new form of smart contract we call reactive smart contracts.   Reactive smart contracts are able to react to on-chain events autonomously and execute their own user defined logic to initiate new transactions. This allows a virtually limitless number of use cases to achieve fully decentralized on-chain automation.

Reactive Network

REACT CRYPTO is trending with significant community excitement following its Reactive Contracts being the first on Ethereum's new EIL testnet, promising unified L2 chains and instant, on-chain automation. Many are highly bullish, anticipating substantial growth as the PRQ migration and related arbitrage concludes, positioning it as a potential core infrastructure for DeFi and Real World Assets.

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

JD.com is trending as investors digest recent disclosures of substantial share buybacks, including a significant repurchase in Q4 2025 that reduced its outstanding shares, yet the stock's price remains largely subdued. The community is sharply divided, with many highlighting its perceived extreme undervaluation and long-term potential in automated logistics, while frustrated holders lament its persistent underperformance and the apparent impact of options market dynamics. This creates a contentious environment for JD, even as some other Chinese tech peers show more upward momentum.

Li Auto, Inc. engages in the design, development, manufacture, and sale of premium smart electric vehicles. Its products include Li MEGA, a high-tech flagship family MPV, Li L9, a six-seat flagship family SUV, and Li L8, a six-seat premium family SUV, and Li L7, a five-seat flagship family SUV. The firm also offers in-house development efforts on its proprietary range extension system, next-generation electric vehicle technology, and smart vehicle solutions. The company was founded by Xiang Li in April 2015 and is headquartered in Beijing, China.

Li Auto Inc - ADR

Li Auto is a hot topic as it navigates intense competition in the Chinese EV market, with recent delivery reports showing both year-over-year declines and better-than-expected sequential performance. The community is actively debating the impact of new model launches like the i6, juxtaposing initial order enthusiasm against competitive pressures from rivals and broader concerns about tariffs affecting Chinese EV exports.

FreightCar America, Inc. is engaged in the manufacturing of railcars and railcar components. It operates through the Manufacturing and Aftermarket segments. The Manufacturing segment includes new railcar manufacturing, used railcar sales, and railcar conversions and rebodies. The Aftermarket segment deals with the selling of forged, cast and fabricated railcar parts and supplies for all railcar types, and provides aftermarket services including safety training, railcar inspections, and preventative maintenance. The firm offers freight cars including box cars, covered hoppers, open top hoppers, gondolas, intermodal, and non-intermodal flat cars that transport dry bulk and containerized freight products. The company was founded in 1901 and is headquartered in Chicago, IL.

FreightCar America Inc

FreightCar America ($RAIL) is drawing attention due to its recent acquisition of Carly Railcar Components, strengthening its aftermarket segment, and the implementation of a stockholder rights plan amidst a disclosed stake from Continental General. The community is actively discussing the potential for M&A activity, believing the company is significantly undervalued, especially given its better-than-expected earnings, growing backlog, and efforts to improve its capital structure. This blend of strategic moves and perceived financial strength is driving current conversation.

Chime Financial, Inc. engages in the design and development of a digital banking application. Its mobile app, Chime, provides online banking, fee-free overdraft, mobile banking, automatic savings, mobile payments, and security and control capabilities. The company was founded by Christopher R. Britt and Ryan King in 2012 and is headquartered in San Francisco, CA.

Chime Financial Inc - Ordinary Shares - Class A

Chime Financial, Inc.

Chime Financial is a focal point of discussion following a period of significant volatility since its IPO, with recent positive earnings and a share repurchase program sparking renewed investor interest. Despite multiple analyst upgrades highlighting undervaluation and growth potential, community sentiment remains deeply divided; while some see a strong buy opportunity at current levels, others are frustrated by persistent selling pressure and historical underperformance, especially when compared to fintech peers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Small Cap Stocks To Keep An Eye On - December 4th

SMX (Security Matters) Public, Spring Valley Acquisition, Direxion Daily META Bull 2X Shares, Polyrizon, and Direxion Daily TSLA Bear 1X Shares are the five Small Cap stocks to watch today, according...

Top Biotech Stocks To Consider - December 4th

Danaher, Polyrizon, Vertex Pharmaceuticals, Medpace, Abivax, Capricor Therapeutics, and Moderna are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech...

Polyrizon Stock Skyrockets After New Data Shows Naloxone Gel Outperforms Marketed Spray

Polyrizon stock is up on new data showing its naloxone hydrogel formulation has stronger and longer-lasting mucosal retention.read more...

What Sparked Polyrizon's (PLRZ) 140% After-Hours Stock Surge?

Polyrizon surged in nearly 140% after-hours trading following preclinical data showing its naloxone hydrogel outperforms a marketed spray and a key manufacturing milestone.read more...

Polyrizon Hits Key Breakthrough That Brings Its Nasal Spray Closer To 2026 Trials

Polyrizon jumps over 100%. The company completes major manufacturing milestone for its proprietary nasal-spray product platform.read more...

<ul class="summary-bullets"><li>The expanded production ensures that the PL-14 spray can be reliably manufactured at higher volumes.</li><li>Following the update, Polyrizon’s stock traded over 82% higher in Tuesday’s premarket.</li><li>The upscaled process is designed to provide clinical trial material (CTM) for studies scheduled to begin in 2026.</li></ul>Polyrizon (PLRZ) announced on Tuesday a major manufacturing milestone for its proprietary nasal spray platform, bringing the company closer to supporting upcoming clinical trials and potential commercial availability.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/PLRZ">Polyrizon’s stock</a> traded over 73% higher in Tuesday’s premarket. On Stocktwits, retail sentiment for the stock improved to ‘extremely bullish’ from ‘bullish’ territory, amid ‘high’ message volumes.&nbsp;<h2 class="st-heading-2">Milestone Achievement</h2>Polyrizon successfully scaled its production process from small laboratory batches to larger, controlled manufacturing runs, validating the key parameters of its PL-14 formulation.&nbsp;The expanded production ensures that the PL-14 spray can be reliably manufactured at higher volumes while maintaining the quality standards necessary for clinical trials.<blockquote>"The process validated our manufacturing strategy.”&nbsp;-Tomer Izraeli, CEO, Polyrizon&nbsp;</blockquote>“With this batch in hand, we are energized and prepared to advance into next batches towards clinical trial material manufacturing, which we believe brings us one step closer to addressing the unmet needs in the nasal spray market."<h2 class="st-heading-2">Preparing For Clinical Trials</h2>The upscaled process is designed to provide clinical trial material (CTM) for studies scheduled to begin in 2026. Polyrizon’s manufacturing procedures align with theU.S. and European regulatory requirements.The PL-14 nasal spray is engineered to create a fast-acting, moisturizing barrier in the nasal cavity, helping trap, isolate, and neutralize airborne allergens before they contact mucosal tissues. Developed using Polyrizon’s proprietary Capture &amp; Contain (C&amp;C) bio-adhesive technology, the spray offers extended, non-pharmacological protection for people exposed to high levels of environmental allergens.&nbsp;PLRZ stock has lost over 99% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mongodb-stock-rises-premarket-as-analysts-increase-price-targets/cLIajIsRE0t">MongoDB’s Atlas Engine Drives A Wave Of Price Target Hikes – Stock Pops In Premarket Trade</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Did Polyrizon Stock Soar Pre-Market Today? 

Polyrizon successfully scaled its production process from small laboratory batches to larger, controlled manufacturing runs, validating the key parameters of its PL-14 formulation. 

Equity

Polyrizon successfully scaled its production process from small laboratory batches to larger, controlled manufacturing runs, validating the key parameters of its PL-14 formulation. 


Polyrizon Ltd (PLRZ)&nbsp;led the pack with a 23% increase in weekly followers after the development-stage biotech company dropped plans to undergo a 1-for-10 reverse stock split, which led to shares surging nearly fourfold on Friday.The Israel-based company specializes in preventing biological threats, including allergens and viruses, from penetrating mucosal tissues — an area that has gained new relevance in the post-COVID-19 world.Last month, Polyrizon reported promising preliminary safety results for its&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/plrz-stock-surges-on-manufacturing-deal-for-trial/cJaVyHWR1U">PL-14</a> Allergy Blocker, a mucoadhesive nasal gel spray designed to create a physical barrier against airborne allergens. The company expects to launch clinical trials in the U.S. and Europe by late 2025 or early 2026.Polyrizon stock has lost over half its value this year.Pheton Holdings (PTHL)&nbsp;saw a 19% rise in retail follower growth over the past week despite the absence of any news catalyst.The Beijing, China-based healthcare solution provider specializes in treatment planning systems for brachytherapy and other related products and services.The company's shares debuted on the Nasdaq in September 2024 and have gained a little over 4% since. However, their performance has been less than stellar year to date, with a loss of over 5%.AirSculpt Technologies (AIRS)&nbsp;posted an 8% jump in weekly Stocktwits follower additions. The body contouring specialist reported better-than-expected quarterly results and forecast full-year revenue of about $160 million to $170 million, which topped Wall Street estimates.Shares of the Miami Beach, Florida-based company, which offers minimally invasive fat removal procedures, have lost over 42% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Polyrizon, Pheton, AirSculpt: Top 3 Healthcare Stocks With Soaring Weekly Retail Interest

A trio of small-cap healthcare stocks caught the attention of retail investors last week, posting sharp jumps in follower growth on Stocktwits. 

Shares of Polyrizon skyrocketed more than 200% to an all-time high on Wednesday, making it the top biotech stock with the most new followers on Stocktwits in the past 24 hours.&nbsp;Trading volume surged 890 times the daily average, reflecting heightened investor interest in the Israel-based biotech company.The massive rally follows Polyrizon’s announcement of a manufacturing agreement with Eurofins CDMO Amatsiaquitaine, a prominent European Good Manufacturing Practice (GMP) manufacturer.&nbsp;This collaboration will supply clinical trial material for Polyrizon’s experimental allergy blocker, PL-14, which is set to enter clinical trials in 2025.The PL-14 allergy blocker is part of Polyrizon’s effort to develop innovative nasal sprays that create a hydrogel-based shield in the nasal cavity, protecting against allergens and viruses.&nbsp;The manufacturing deal secures a compliant supply chain for the clinical trial, marking a key milestone for the development-stage biotech firm.Retail chatter on Stocktwits has been overwhelmingly bullish.<stembedurl>https://stocktwits.com/TraderUKBoyy/message/597012617</stembedurl><stembedurl>https://stocktwits.com/Dollarpee/message/597017164</stembedurl>Polyrizon’s stock had a rocky start on the Nasdaq, debuting at the end of October with a disappointing IPO.&nbsp;The company priced 958,903 units at $4.38 per unit, with each unit including one ordinary share and three warrants exercisable at the same price. Shares dropped more than 64% post IPO.Despite the poor debut, Polyrizon has gained 90% so far this year following Wednesday’s surge, although it remains below its IPO price.&nbsp;Over the past month, the stock has seen a meteoric rise in popularity, adding 1,576% more followers on Stocktwits amid a 10,300% spike in message volume.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Polyrizon's Retail Following Booms As Biotech Stock Triples On Manufacturing Deal For Allergy Blocker Trial

This collaboration will supply clinical trial material for Polyrizon’s experimental allergy blocker, PL-14, which is set to enter clinical trials in 2025.

Polyrizon Ltd. is a development stage biotech company, which engages in the development of nasal hydrogels. It provides barriers from the interaction of biological assaults, including a new strain of coronavirus, influenza, allergens and other airborne pathogens with the nasal epithelial tissue. The company was founded by Tomer Izraeli in January 2005 and is headquartered in Raanana, Israel.

PLRZ
Polyrizon Ltd. Ordinary Shares

Feed

News

Sentiment

Fundamentals

Info

Latest PLRZ News

PLRZPolyrizon Ltd. Ordinary Shares